Hosted on MSN1d
OrexiBurn: We Tested It—Here's Our Honest Orexi Burn Review After 108 Days!
In today’s busy world, staying fit and energized can feel like a challenge. Many people are looking for natural ways t ...
Nature4y
Fighting apathy and lack of awareness in the struggle against substance use disorder
Two identified orexin receptors (OX1 and OX2 ... For example, a recent systematic review and meta-analysis revealed that the prevalence of any substance use disorder in treatment-seeking patients ...
Seeking Alpha19d
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative opportunity in a $7.3 billion market by 2032. With $908.9 million in liquidity and a ...
pharmaphorum1y
Idorsia is first to EU market with orexin insomnia drug
Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.
Morningstar8d
Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea
Daridorexant is a dual orexin receptor antagonist being developed ... Recent data from Korea’s Health Insurance Review and Assessment Service (HIRA) revealed that the number of chronic insomnia ...
TMCnet9d
Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia; QUVIVIQ™ (daridorexant) 25 and 50 mg was recently a ...